Meyka Pro banner
Neuronetics, Inc.

Neuronetics, Inc. Fundamental Analysis (NASDAQ: STIM)

STIMNASDAQ
HealthcareMedical - Devices
$3.00
$0.09(2.91%)
U.S. Market opens in 54h 41m

Neuronetics, Inc. Fundamental Analysis (NASDAQ: STIM)

Neuronetics, Inc. (NASDAQ: STIM) shows moderate financial fundamentals with a PE ratio of -6.99, profit margin of -19.62%, and ROE of -1.51%. The company generates $0.2B in annual revenue with strong year-over-year growth of 99.17%.

Key Strengths

PEG Ratio-0.06
Current Ratio1.88

Areas of Concern

ROE-1.51%
Operating Margin-14.74%
We analyze STIM's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -136.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-136.1/100

We analyze STIM's fundamental strength across five key dimensions:

Efficiency Score

Weak

STIM struggles to generate sufficient returns from assets.

ROA > 10%
-23.14%

Valuation Score

Excellent

STIM trades at attractive valuation levels.

PE < 25
-6.99
PEG Ratio < 2
-0.06

Growth Score

Excellent

STIM delivers strong and consistent growth momentum.

Revenue Growth > 5%
99.17%
EPS Growth > 10%
57.25%

Financial Health Score

Moderate

STIM shows balanced financial health with some risks.

Debt/Equity < 1
4.85
Current Ratio > 1
1.88

Profitability Score

Weak

STIM struggles to sustain strong margins.

ROE > 15%
-150.56%
Net Margin ≥ 15%
-19.62%
Positive Free Cash Flow
No

Key Financial Metrics

Is STIM Expensive or Cheap?

P/E Ratio

STIM trades at -6.99 times earnings. This suggests potential undervaluation.

-6.99

PEG Ratio

When adjusting for growth, STIM's PEG of -0.06 indicates potential undervaluation.

-0.06

Price to Book

The market values Neuronetics, Inc. at 12.01 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

12.01

EV/EBITDA

Enterprise value stands at -6.67 times EBITDA. This is generally considered low.

-6.67

How Well Does STIM Make Money?

Net Profit Margin

For every $100 in sales, Neuronetics, Inc. keeps $-19.62 as profit after all expenses.

-19.62%

Operating Margin

Core operations generate -14.74 in profit for every $100 in revenue, before interest and taxes.

-14.74%

ROE

Management delivers $-1.51 in profit for every $100 of shareholder equity.

-1.51%

ROA

Neuronetics, Inc. generates $-23.14 in profit for every $100 in assets, demonstrating efficient asset deployment.

-23.14%

Following the Money - Real Cash Generation

Operating Cash Flow

Neuronetics, Inc. generates limited operating cash flow of $-8.90M, signaling weaker underlying cash strength.

$-8.90M

Free Cash Flow

Neuronetics, Inc. generates weak or negative free cash flow of $-9.82M, restricting financial flexibility.

$-9.82M

FCF Per Share

Each share generates $-0.14 in free cash annually.

$-0.14

FCF Yield

STIM converts -4.80% of its market value into free cash.

-4.80%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-6.99

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.06

vs 25 benchmark

P/B Ratio

Price to book value ratio

12.01

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.35

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

4.85

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.88

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.51

vs 25 benchmark

ROA

Return on assets percentage

-0.23

vs 25 benchmark

ROCE

Return on capital employed

-0.22

vs 25 benchmark

How STIM Stacks Against Its Sector Peers

MetricSTIM ValueSector AveragePerformance
P/E Ratio-6.9930.97 Better (Cheaper)
ROE-150.56%515.00% Weak
Net Margin-19.62%30197.00% Weak
Debt/Equity4.850.53 Weak (High Leverage)
Current Ratio1.885.71 Neutral
ROA-23.14%-16.00% (disorted) Weak

STIM outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Neuronetics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-13.50%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

59.43%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

79.50%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ